Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent reduced the risk of disease recurrence or death by 80%.- AstraZeneca

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent. Results will be presented during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on 31 May (abstract #LBA5). In the primary endpoint of DFS in patients with Stage II and IIIA disease, adjuvant treatment (after surgery) with Tagrisso reduced the risk of disease recurrence or death by 83% (based on a hazard ratio [HR] of 0.17; 95% confidence interval [CI] 0.12, 0.23; p<0.0001). dfs results in the overall trial population, stage ib through iiia, a key secondary endpoint, demonstrated a reduction in the risk of disease recurrence or death of 79% (based on a hr of 0.21; 95% ci 0.16, 0.28; p><0.0001). at two years, 89% of patients in the trial treated with tagrisso remained alive and disease free versus 53% on placebo. consistent dfs results were seen across all subgroups, including patients who were treated with surgery followed by chemotherapy and those who received surgery only, as well as in asian and non-asian patients. in april 2020, an independent data monitoring committee recommended for the phase iii adaura trial to be unblinded two years early based on its determination of overwhelming efficacy. at the time of data cut-off, overall survival (os) data favoured tagrisso, but were not mature. the trial will continue to assess os as a secondary endpoint. the safety and tolerability of tagrisso in this trial was consistent with previous trials in the metastatic setting. adverse events at grade 3 or higher from all causes occurred in 10% of patients in the tagrisso arm versus 3% in the placebo arm as assessed by the investigator. tagrisso is approved for the 1st-line treatment of patients with locally advanced or metastatic egfrm nsclc in the us, japan, china, the eu and many other countries around the world.>